Refine
Keywords
- - (3)
- FcγRIIa (1)
- PF4 (1)
- aPF4/H antibodies (1)
- antiāPF4/heparin antibodies (1)
- bleeding tendency (1)
- blood smear (1)
- hereditary thrombocytopenias (1)
- immunofluorescence (1)
- inherited platelet disorders (1)
Institute
- Institut für Immunologie u. Transfusionsmedizin - Abteilung Immunologie (3) (remove)
Abstract
Background
Heparin induced thrombocytopenia (HIT) is likely a misdirected bacterial host defense mechanism. Platelet factor 4 (PF4) binds to polyanions on bacterial surfaces exposing neoāepitopes to which HIT antibodies bind. Platelets are activated by the resulting immune complexes via FcγRIIA, release bactericidal substances, and kill Gramānegative Escherichia coli.
Objectives
To assess the role of PF4, antiāPF4/H antibodies and FcγRIIa in killing of Gramāpositive bacteria by platelets.
Methods
Binding of PF4 to proteināA deficient Staphylococcus aureus (SA113Īspa) and nonāencapsulated Streptococcus pneumoniae (D39Īcps) and its conformational change were assessed by flow cytometry using monoclonal (KKO,5B9) and patient derived antiāPF4/H antibodies. Killing of bacteria was quantified by counting colony forming units (cfu) after incubation with platelets or platelet releasate. Using flow cytometry, platelet activation (CD62Pāexpression, PACā1 binding) and phosphatidylserine (PS)āexposure were analyzed.
Results
Monoclonal and patientāderived antiāPF4/H antibodies bound in the presence of PF4 to both S.Ā aureus and S.Ā pneumoniae (1.6āfold increased fluorescence signal for human antiāPF4/H antibodies to 24.0āfold increase for KKO). Staphylococcus aureus (5.5Ā ĆĀ 104cfu/mL) was efficiently killed by platelets (2.7Ā ĆĀ 104cfu/mL) or their releasate (2.9Ā ĆĀ 104cfu/mL). Killing was not further enhanced by PF4 or antiāPF4/H antibodies. Blocking FcγRIIa had no impact on killing of S.Ā aureus by platelets. In contrast, S.Ā pneumoniae was not killed by platelets or releasate. Instead, after incubation with pneumococci platelets were unresponsive to TRAPā6 stimulation and exposed high levels of PS.
Conclusions
AntiāPF4/H antibodies seem to have only a minor role for direct killing of Gramāpositive bacteria by platelets. Staphylococcus aureus is killed by platelets or platelet releasate. In contrast, S.Ā pneumoniae affects platelet viability.
Abstract
Background
Heparins are usually produced from animal tissues. It is now possible to synthesize heparins. This provides the abilities to overcome shortages of heparin, to optimize biological effects, and to reduce adverse drug effects. Heparins interact with platelet factor 4 (PF4), which can induce an immune response causing thrombocytopenia. This side effect is called heparināinduced thrombocytopenia (HIT). We characterized the interaction of PF4 and HIT antibodies with oligosaccharides of 6ā, 8ā, 10ā, and 12āmer size and a hypersulfated 12āmer (S12āmer).
Methods
We utilized multiple methodologies including isothermal calorimetry, circular dichroism spectroscopy, single molecule force spectroscopy (SMFS), enzyme immunosorbent assay (EIA), and platelet aggregation test to characterize the interaction of synthetic heparin analogs with PF4 and antiāPF4/heparin antibodies.
Results
The synthetic heparinālike compounds display stronger binding characteristics to PF4 than animalāderived heparins of corresponding lengths. Upon complexation with PF4, 6āmer and S12āmer heparins showed much lower enthalpy, induced less conformational changes in PF4, and interacted with weaker forces than 8ā, 10ā, and 12āmer heparins. AntiāPF4/heparin antibodies bind more weakly to complexes formed between PF4 and heparinsĀ ā¤Ā 8āmer than with complexes formed between PF4 and heparinsĀ ā„Ā 10āmer. Addition of one sulfate group to the 12āmer resulted in a S12āmer, which showed substantial changes in its binding characteristics to PF4.
Conclusions
We provide a template for characterizing interactions of newly developed heparinābased anticoagulant drugs with proteins, especially PF4 and the resulting potential antigenicity.